NeoGenomics prices $275M convertible notes due 2032; to repurchase $276M of existing notes

NEOGENOMICS INC

$275M principal of 0.75% convertible notes due 2032; initial purchasers have option for additional $41.25M.
Initial conversion price ~$14.16/share, a 35% premium to $10.49 closing price on June 16, 2026.
Net proceeds ~$266.15M; ~$25M used for capped call transactions (cap price $20.98/share).
Concurrently repurchasing $276M of existing 0.25% convertible notes due 2028 for ~$263.19M.
Also plans to repurchase up to $25M of common stock from certain note purchasers; offering expected to close June 22, 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.